Eli Lilly and Company has announced plans to invest an additional $450 million to expand its manufacturing site in Research Triangle Park, North Carolina. The expansion includes additional parenteral filling, device assembly, and packaging capacity to support increased demand for Lilly’s incretin products that treat diabetes. 

Lilly says it is on track to achieve a previously announced goal made in November 2022 to double incretin capacity by the end of this year (2023). The company anticipates initial production at Research Triangle Park to begin this year (2023), with preparations for inspections by the US Food and Drug Administration ongoing. 

The next phase of the expansion is slated to be fully operational in 2027 and will create at least 100 new jobs, primarily manufacturing personnel. 

Since 2020, Lilly has committed roughly $4 billion to new manufacturing facilities in North Carolina, including $1.7 billion for the development and expansion of its site at Research Triangle Park.  

Source: Eli Lilly and Company